Benedikt Schrage

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1936335/publications.pdf

Version: 2024-02-01

77 papers	2,481 citations	279701 23 h-index	214721 47 g-index
77 all docs	77 docs citations	77 times ranked	2436 citing authors

#	Article	IF	Citations
1	Alcohol intake and total mortality in 142â€‰960 individuals from the MORGAM Project: a populationâ€based study. Addiction, 2022, 117, 312-325.	1.7	22
2	Diastolic dysfunction in individuals with and without heart failure with preserved ejection fraction. Clinical Research in Cardiology, 2022, 111, 416-427.	1.5	3
3	Cardiac resynchronization therapy with or without defibrillator in patients with heart failure. Europace, 2022, 24, 48-57.	0.7	10
4	Intracranial haemorrhage in adult patients on venoarterial extracorporeal membrane oxygenation. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 303-311.	0.4	4
5	Early risk stratification in patients with cardiogenic shock irrespective of the underlying causeÂâ€“Âthe Cardiogenic Shock Score. European Journal of Heart Failure, 2022, 24, 657-667.	2.9	26
6	Patient profile and outcomes associated with followâ€up in specialty vs. primary care in heart failure. ESC Heart Failure, 2022, 9, 822-833.	1.4	23
7	OUP accepted manuscript. European Heart Journal: Acute Cardiovascular Care, 2022, , .	0.4	0
8	Percutaneous Transvalvular Microaxial Flow Pump Support in Cardiology. Circulation, 2022, 145, 1254-1284.	1.6	29
9	Heart failure in the general population and impact of the 2021 European Society of Cardiology Heart Failure Guidelines. ESC Heart Failure, 2022, 9, 2157-2169.	1.4	10
10	Extracorporeal membrane oxygenation. Deutsches Ärzteblatt International, 2022, , .	0.6	5
11	Establishing a robotic-assisted PCI program: experiences at a large tertiary referral center. Heart and Vessels, 2022, 37, 1669-1678.	0.5	3
12	Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock. Journal of the American College of Cardiology, 2022, 79, 1949-1962.	1.2	36
13	Association Between the Acidemia, Lactic Acidosis, and Shock Severity With Outcomes in Patients With Cardiogenic Shock. Journal of the American Heart Association, 2022, 11, e024932.	1.6	15
14	Predictors of primary prevention implantable cardioverterâ€defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and allâ€cause mortality. European Journal of Heart Failure, 2022, 24, 1212-1222.	2.9	10
15	Enough iron in transcatheter aortic valve implantation already. European Journal of Heart Failure, 2022, 24, 1280-1281.	2.9	0
16	Lower socioeconomic status predicts higher mortality and morbidity in patients with heart failure. Heart, 2021, 107, 229-236.	1.2	26
17	Sealing of Coronary Perforations With a Second-Generation Covered Stent Graft - Results From the PAST-PERF Registry. Cardiovascular Revascularization Medicine, 2021, 25, 20-26.	0.3	9
18	Impact of therapeutic hypothermia on bleeding events in adult patients treated with extracorporeal life support peri-cardiac arrest. Journal of Critical Care, 2021, 62, 12-18.	1.0	12

#	Article	IF	Citations
19	Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock. ESC Heart Failure, 2021, 8, 1295-1303.	1.4	69
20	Sex differences in patients with cardiogenic shock. ESC Heart Failure, 2021, 8, 1775-1783.	1.4	17
21	Use of <scp>sodiumâ€“glucose</scp> coâ€transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. European Journal of Heart Failure, 2021, 23, 1012-1022.	2.9	33
22	Importance of swift event adjudication of endpoints for adequate reporting to data and safety monitoring boards in clinical trialsâ€"lessons from CULPRIT-SHOCK. Trials, 2021, 22, 197.	0.7	0
23	Non-immune risk predictors of cardiac allograft vasculopathy: Results from the U.S. organ procurement and transplantation network. International Journal of Cardiology, 2021, 331, 57-62.	0.8	9
24	Response by Schrage and Westermann to Letters Regarding Article, â€œLeft Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Studyâ€• Circulation, 2021, 143, e1024.	1.6	10
25	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. Journal of Cardiac Failure, 2021, 27, 888-895.	0.7	14
26	Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials. European Journal of Heart Failure, 2021, 23, 1942-1951.	2.9	25
27	Seasonal trends of incidence and outcomes of cardiogenic shock : findings from a large, nationwide inpatients sample with 441,696 cases. Critical Care, 2021, 25, 325.	2.5	1
28	Study design and rationale of the pAtients pResenTing with cOngenital heaRt dIseAse Register (ARTORIAâ€R). ESC Heart Failure, 2021, 8, 5542-5550.	1.4	4
29	Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the <scp>S</scp>wedish <scp>H</scp>eart <scp>F</scp>ailure <scp>R</scp>egistry. European Journal of Heart Failure, 2021, 23, 1844-1854.	2.9	42
30	Regional differences in presentation characteristics, use of treatments and outcome of patients with cardiogenic shock: Results from multicenter, international registry. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2021, 165, 291-297.	0.2	3
31	Gender differences in characteristics and outcomes in heart failure patients referred for endâ€stage treatment. ESC Heart Failure, 2021, , .	1.4	4
32	Influence of age and shock severity on short-term survival in patients with cardiogenic shock. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 604-612.	0.4	45
33	Association of iron deficiency with incident cardiovascular diseases and mortality in the general population. ESC Heart Failure, 2021, 8, 4584-4592.	1.4	13
34	Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRITâ€SHOCK Substudy. Journal of the American Heart Association, 2021, 10, e021150.	1.6	1
35	Extracorporeal Membrane Oxygenation Evolution: LV Unloading Strategies. JTCVS Open, 2021, , .	0.2	0
36	Differences in the Treatment of Acute Coronary Syndrome in the Pre-COVID and COVID Era: An Analysis from Two German High-Volume Centers. Journal of Cardiovascular Development and Disease, 2021, 8, 145.	0.8	4

#	Article	IF	Citations
37	Cytokine-Mediated Alterations of Human Cardiac Fibroblastâ€™s Secretome. International Journal of Molecular Sciences, 2021, 22, 12262.	1.8	8
38	Association between betaâ€blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity scoreâ€matched analysis from the Swedish Heart Failure Registry. European Journal of Heart Failure, 2020, 22, 103-112.	2.9	27
39	Risk prediction of in-hospital mortality in patients with venoarterial extracorporeal membrane oxygenation for cardiopulmonary support: The ECMO-ACCEPTS score. Journal of Critical Care, 2020, 56, 100-105.	1.0	27
40	Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation. Circulation, 2020, 142, 2095-2106.	1.6	269
41	Septic perimyocarditis due to a rightâ€sided infective endocarditis of atypical morphology in a 33â€yearâ€old woman. Clinical Case Reports (discontinued), 2020, 8, 1486-1488.	0.2	0
42	Heart Failure in Patients Undergoing Elective and Emergency Noncardiac Surgery: Still a Poorly Addressed Risk Factor. Journal of Cardiac Failure, 2020, 26, 1034-1042.	0.7	7
43	Clinical characteristics and outcomes of patients with adult congenital heart disease listed for heart and heartâ€™lung transplantation in the Eurotransplant region. Journal of Heart and Lung Transplantation, 2020, 39, 1238-1249.	0.3	8
44	Nonâ€insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. ESC Heart Failure, 2020, 7, 3438-3451.	1.4	13
45	Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. International Journal of Cardiology, 2020, 313, 76-82.	0.8	30
46	Procedural volume and outcomes in patients undergoing VA-ECMO support. Critical Care, 2020, 24, 291.	2.5	32
47	Response by Schrage et al to Letter Regarding Article, â€œAssociation Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registryâ€. Circulation, 2020, 141, e648-e649.	1.6	1
48	Iron deficiency is a common disorder in general population and independently predicts all-cause mortality: results from the Gutenberg Health Study. Clinical Research in Cardiology, 2020, 109, 1352-1357.	1.5	21
49	Detailed interpretation of ECMO-ACCEPTS score. Journal of Critical Care, 2020, 60, 327.	1.0	0
50	Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 5.0: De-escalate and ambulate. Journal of Critical Care, 2020, 57, 259-263.	1.0	47
51	Application of the SCAI classification in a cohort of patients with cardiogenic shock. Catheterization and Cardiovascular Interventions, 2020, 96, E213-E219.	0.7	122
52	Comparison of Cardiovascular Risk Factors in European Population Cohorts for Predicting Atrial Fibrillation and Heart Failure, Their Subsequent Onset, and Death. Journal of the American Heart Association, 2020, 9, e015218.	1.6	13
53	Mitral stenosis and atrial fibrillation. Heart, 2020, 106, 713-713.	1.2	4
54	Patient Characteristics, Treatment and Outcome in Non-Ischemic vs. Ischemic Cardiogenic Shock. Journal of Clinical Medicine, 2020, 9, 931.	1.0	28

#	Article	IF	Citations
55	Switching to Impella 5.0 decreases need for transfusion in patients undergoing temporary mechanical circulatory support. Journal of Critical Care, 2020, 57, 253-258.	1.0	13
56	Hemodynamic Effects of Mechanical Circulatory Support Devices in Ventricular Septal Defect. Circulation: Heart Failure, 2019, 12, e005981.	1.6	62
57	Neuron-specific-enolase as a predictor of the neurologic outcome after cardiopulmonary resuscitation in patients on ECMO. Resuscitation, 2019, 136, 14-20.	1.3	33
58	Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure. Circulation, 2019, 140, 1530-1539.	1.6	78
59	Macrophage Migration Inhibitory Factor (MIF) Expression Increases during Myocardial Infarction and Supports Pro-Inflammatory Signaling in Cardiac Fibroblasts. Biomolecules, 2019, 9, 38.	1.8	20
60	Impella 5.0 therapy as a bridge-to-decision option for patients on extracorporeal life support with unclear neurological outcomes. European Journal of Cardio-thoracic Surgery, 2019, 56, 1031-1036.	0.6	27
61	Reply. JACC: Heart Failure, 2019, 7, 364-365.	1.9	2
62	Mechanical circulatory support devices in cardiogenic shock and acute heart failure: current evidence. Current Opinion in Critical Care, 2019, 25, 391-396.	1.6	19
63	Response by Schrage et al to Letter Regarding Article, â€œImpella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Matched-Pair IABP-SHOCK II Trial 30-Day Mortality Analysisâ€• Circulation, 2019, 140, e559-e560.	1.6	5
64	Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock. Circulation, 2019, 139, 1249-1258.	1.6	353
65	Distinct Hemodynamic Changes After Interventional Mitral Valve Edgeâ€toâ€Edge Repair in Different Phenotypes of Heart Failure: An Integrated Hemodynamic Analysis. Journal of the American Heart Association, 2018, 7, .	1.6	7
66	Effective treatment with a new protocol using tissue-type plasminogen activator thrombolysis for pump thrombosis with the HVAD device. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 766-770.	0.4	13
67	Deâ€escalation of support with venoâ€arterial extracorporeal membrane oxygenation and Impella for cardiogenic shock: reply. European Journal of Heart Failure, 2018, 20, 622-623.	2.9	0
68	Unloading of the Left Ventricle During Venoarterial Extracorporeal Membrane Oxygenation Therapy in CardiogenicÂShock. JACC: Heart Failure, 2018, 6, 1035-1043.	1.9	105
69	Venoarterial Extracorporeal Membrane Oxygenation for Cardiopulmonary Support. Circulation, 2018, 138, 2298-2300.	1.6	92
70	Severe ischaemic cardiogenic shock with cardiac arrest and prolonged asystole: a case report. European Heart Journal - Case Reports, 2018, 2, yty088.	0.3	0
71	Adherence to Mediterranean diet, high-sensitive C-reactive protein, and severity of coronary artery disease: Contemporary data from the INTERCATH cohort. Atherosclerosis, 2018, 275, 256-261.	0.4	36
72	Right Ventricular Index for Risk Stratification of Patients with Pulmonary Arterial Hypertension. Respiration, 2018, 96, 249-258.	1.2	4

#	Article	IF	Citations
73	Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromesâ€"Why Is It Not Used in Clinical Practice?. Thrombosis and Haemostasis, 2018, 118, 1528-1534.	1.8	4
74	Lipid Management After First Diagnosis of Coronary Artery Disease: Contemporary Results From an Observational Cohort Study. Clinical Therapeutics, 2017, 39, 2311-2320.e2.	1.1	10
75	Concomitant implantation of Impella^{Â®} on top of venoâ€arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. European Journal of Heart Failure, 2017, 19, 404-412.	2.9	402
76	Percutaneous coronary intervention for ostial and bifurcation lesions using the Szabo technique: a single center experience. Minerva Cardiology and Angiology, 2017, 65, 331-335.	0.4	1
77	Radiation exposure during the implantation of bioabsorbable vascular scaffolds versus drug-eluting stents in non-complex coronary lesions: a matched-cohort study. Minerva Cardiology and Angiology, 2016, 65, 1-7.	0.4	1